Áttétes emlőrák: vizsgálatok itt: Csehország

In Csehország 12 Also abroad 610

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

2. fázisTaking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Olomouc, Prague
Életkor
18 év and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
3. fázisTaking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Brno-Stred, Hořovice, Hradec Králové, Nový Jičín, Olomouc, Prague, Prague 2
Életkor
18 év and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
2/3. fázisTaking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Brno, Hradec Králové, Nový Jičín, Prague
Életkor
18 év and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
3. fázisTaking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Brno-Stred, Hořovice, Novy Hradec Kralove, Olomouc, Prague
Életkor
18 év and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Nový Jičín, Prague
Életkor
18 év and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
3. fázisTaking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
České Budějovice, Olomouc, Ostrava-Poruba, Prague
Életkor
18 év and over
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
3. fázisTaking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
Brno-Stred, Hořovice, Hradec Králové, Olomouc, Prague
Életkor
18 év and over
People
1180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
3. fázisTaking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Hořovice, Liberec I-Stare Mesto, Olomouc, Prague, Zlin
Életkor
18 év and over
People
1000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
1/2. fázisTaking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Brno-Stred
Életkor
18 év to 100 év
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
3. fázisTaking people
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Where
Brno-Stred, Hořovice, Liberec I-Stare Mesto, Olomouc, Prague, Zlin
Életkor
18 év and over
People
300 worldwide
Run by
MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00
1/2. fázisTaking people
Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
Where
Olomouc
Életkor
18 év and over
People
55 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521911-38-00 · EU 2025-521911-38-00
3. fázisNot yet taking people in Csehország
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Where
Hořovice, Olomouc, Prague
Életkor
18 év and over
People
300 worldwide
Run by
Rovi Pharmaceuticals Laboratories
See details and how to joinNCT07340658 · EU 2025-524846-85-00